Search for content, post, videos

BioArctic expands portfolio with Parkinson’s disease project

Gunilla Osswald

The new project, PD-BT2238, combines a selective alpha-synuclein oligomer targeting antibody with BioArctic’s Brain Transporter technology, to increase exposure of the antibody in the brain, with the aim of increasing efficacy of a potential treatment in Parkinson’s disease.

BioArctic’s aim is to develop an antibody treatment targeting soluble aggregated forms of alpha-synuclein, a protein that is genetically and neuropathologically linked to Parkinson’s disease and believed to be an important initiating factor in the disease development, the company states in a press release. The PD-BT2238 project is a second-generation alpha-synuclein antibody, combining an oligomer-selective alpha-synuclein antibody with BioArctic’s Brain Transporter technology, designed to improve brain exposure.

“BioArctics proprietary Brain Transporter technology has the opportunity to improve brain exposure and thereby the efficacy of biologic treatments for various neurodegenerative diseases.”

“BioArctics proprietary Brain Transporter technology has the opportunity to improve brain exposure and thereby the efficacy of biologic treatments for various neurodegenerative diseases. We are therefore very excited to also bring this technology into our Parkinson’s disease project portfolio,” says Gunilla Osswald, BioArctic’s CEO.

BioArctic’s alpha-synuclein frontrunner BAN0805 is currently in preparation for phase 2, while potential partnerships are being explored. Phase 1 data showed that BAN0805 was well tolerated, supporting continuation into phase 2 with once-monthly dosing.

Photo of Gunilla Osswald: BioArctic

Advertisement